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Summary (246/250 max) 
Aim: To investigate the efficacy and safety of intravenous retosiban in women with 
spontaneous preterm labour.  
Methods: Randomised, double-blind, placebo-controlled, phase 2 trial. Retosiban was 
administered intravenously for 48 hours to women in spontaneous preterm labour between 
30
0/7 
and 35
6/7 
weeks’ gestation with an uncomplicated singleton pregnancy in an in-patient 
obstetric unit. Outcome measures were uterine quiescence (primary endpoint), days to 
delivery, preterm delivery, and safety. 
Results: Uterine quiescence was achieved in 62% of women who received retosiban (n=30) 
compared with 41% who received placebo (n=34). The relative risk (RR) was 1.53 (95% 
credible interval [CrI]: 0.98, 2.48; NS). Retosiban resulted in a significant increase in time to 
delivery compared with placebo (mean difference, 8.2 days; 95% CrI: 2.7, 13.74); this 
difference was consistent across all gestational ages. The proportion of preterm births in the 
retosiban and placebo groups was 18.7% (95% CrI: 7.4%, 33.7%) and 47.2% (95% CrI: 
31.4%, 63.4%), respectively. The RR of preterm birth in women treated with retosiban was 
0.38 (95% CrI: 0.15, 0.81). There were no deliveries within 7 days in the retosiban group, but 
there were six (17.6%) births in the placebo group. Maternal, fetal, and neonatal adverse 
events were similar in the retosiban and placebo groups.  
Conclusions: Intravenous administration of retosiban in women with spontaneous preterm 
labour was associated with a greater than 1-week increase in time to delivery compared with 
placebo, a significant reduction in preterm deliveries, a non-significant increase in uterine 
quiescence, and a favourable safety profile.  
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What is known about this subject 
 Preterm birth is the largest single cause of infant morbidity and mortality; risks 
increase with earlier gestational age. 
 Current tocolytics have not been demonstrated to improve neonatal outcome. 
 A tocolytic that significantly prolongs pregnancy may improve neonatal and infant 
outcomes. 
What this study adds 
 Retosiban prolonged pregnancy and reduced preterm birth. 
 Treatment was well tolerated and there was no indication of a safety issue for mother, 
fetus, or newborn. 
 The results demonstrate proof-of-concept in the treatment of threatened spontaneous 
preterm labour.  
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INTRODUCTION  
Preterm birth is the largest single cause of infant morbidity and mortality and is frequently 
associated with long-term disability [1–4]. Current tocolytics may not be effective in delaying 
delivery for a number of possible reasons [1, 5–7]: the drug target may be inappropriate, the 
plasma concentration may be ineffective, or redundant mechanisms may allow the process of 
labour to continue. Clinicians remain optimistic that an effective tocolytic will be developed 
which can significantly prolong pregnancy and improve neonatal and infant outcomes in 
appropriate pregnancies. 
Atosiban, a mixed vasopressin (V1a)/oxytocin receptor antagonist, is licensed in the European 
Union as a tocolytic for parenteral administration [8]. There are no tocolytics currently 
approved in North America. Many therapies are used off-label throughout the world, 
including beta-sympathomimetics, prostaglandin synthase inhibitors, and calcium channel 
blockers [9], although none have been conclusively demonstrated to delay delivery and 
improve neonatal or infant outcomes. Retosiban, a specific, high-affinity oxytocin receptor 
antagonist, is now in development for the inhibition of uterine contractions in spontaneous 
preterm labour. Retosiban is an oxazole diketopiperazine oxytocin antagonist with good 
bioavailability and nanomolar affinity for the human oxytocin receptor (Ki=0.65 nM), with 
>1400-fold selectivity over the closely related vasopressin receptors [10]. Nomenclature for 
the vasopressin and oxytocin receptors is as specified in the Guide to Receptors and Channels 
(GRAC), 5th edition [11].
 
 
There is evidence from in vitro and in vivo studies that retosiban inhibits spontaneous and 
induced uterine contractions. Phase 1 studies have demonstrated safety in non-pregnant 
volunteers (unpublished data on file, study OTA 105101; Michael Fossler, PharmD, PhD, 
FCP, Senior Director, CPMS – US, RD Projects Clinical Platforms & Sciences, 
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GlaxoSmithKline, King of Prussia, PA, USA) and retosiban has been evaluated in pregnant 
women to determine the dose-range and confirm proof of mechanism based on suppression of 
uterine contractions [12,13]. The pilot dose ranging studies were done on 29 women in 
threatened preterm labour between 34 and 35
+6
 weeks’ gestation. These studies (to be 
published separately) demonstrated rapid absorption of retosiban with plasma concentrations 
consistent with nonpregnant volunteers. The safety profile was similar to placebo. Retosiban 
was associated with a reduction in uterine activity and a marked increase in the number of 
days to delivery.  In the current report, proof-of-concept was further extended to confirm the 
efficacy and safety of intravenous retosiban in women experiencing spontaneous preterm 
labour between 30
0/7 
and 35
6/7 weeks’ gestation with an uncomplicated singleton pregnancy.  
  
This article is protected by copyright. All rights reserved. 
METHODS 
Study Design 
This was a double-blind, placebo-controlled study in women admitted with spontaneous 
preterm labour between 30
0/7 
and 35
6/7 
weeks’ gestation (registration number NCT00404768; 
http://clinicaltrials.gov/ct2/show/NCT00404768?term=be+NCT00404768&rank=1.) 
Eligible women were stratified by gestational age, 30
0/7
 to
 
32
6/7 
weeks or 33
0/7
 to 35
6/7 
weeks, 
and randomised 1:1 to intravenous retosiban or placebo. Magnesium sulphate for 
neuroprotection and antenatal steroids were allowed.  
The retosiban dosing regimen was designed to achieve a mean steady-state concentration of 
75 ng/ml (informed by pre-clinical data, the dose-ranging study, and studies in non-pregnant 
healthy volunteers) using a loading dose of 6 mg over 5 minutes and a continuous infusion of 
6 mg/hour over 48 hours. At any point after 1 hour of receiving the 6-mg/hour rate, a single 
dose increase was permitted in women who did not respond to treatment. In this case, the 
infusion rate could be increased to 12 mg/hour after an additional 6-mg loading dose. An 
adequate treatment response was defined as a clinically relevant reduction in the frequency of 
contractions without an increase in cervical dilatation. Women who did not respond to the 
dose increase could discontinue study medication and receive an alternative rescue tocolytic 
at the discretion of the investigator.  
 
A group sequential design was used with up to three planned interim analyses (four planned 
cohorts of 16 women each). At each interim analysis, the study could have been stopped for 
success or futility based on a priori stopping rules.  
 
Eligible Women 
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Eligible women were 18 to 45 years of age, had a singleton pregnancy between 30
0/7
 and 35
6/7
 
weeks’ gestation based on best available obstetric estimate, were having six or more uterine 
contractions per hour of at least 30 seconds’ duration by external cardiotocography (CTG) 
with cervical dilatation ≥1 to ≤4 cm, and had intact fetal membranes.  
 
Excluded were women with indications for delivery, such as pre-eclampsia or fetal 
compromise; women with contraindications to tocolysis, such as clinically apparent 
intrauterine infection or placental abruption; and women with comorbid conditions with the 
potential to complicate pregnancy and outcomes, such as hypertension, insulin-dependent 
diabetes, or substance abuse.  
 
Procedure 
Following confirmation of eligibility, maternal examination and investigations were done 
(vital signs; 12-lead electrocardiogram (ECG); biochemistry, haematology, and urinalysis). 
An ultrasound was done to determine amniotic fluid index (AFI) and a CTG for fetal heart 
rate monitoring. These tests were not repeated if they had been done in the 6 hours before 
consent. Within 1 hour before dosing, the contraction rate and duration were determined, a 
vaginal examination was done to assess cervical dilatation, and fetal heart rate was recorded. 
Dosing began at time zero. After the start of treatment, the following assessments were 
conducted at specified time points: maternal blood pressure, heart rate, ECG, uterine 
contractions, physical examination, clinical laboratory tests, AFI, and fetal heart rate. Women 
who discontinued study medication and their infants were followed for safety.  
 
Study Endpoints 
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The primary pharmacodynamic endpoint (response rate) was the proportion of women who 
achieved and maintained uterine quiescence, defined as four or fewer contractions per hour 
and <1 cm change in cervical dilatation at hour 6. The principal efficacy endpoints were days 
to delivery (a tertiary endpoint) and preterm births (<37 weeks). The safety endpoints were 
aimed at detecting adverse drug effects based on maternal monitoring (ECG, laboratory 
results, vital signs, and adverse events), fetal monitoring (CTG, modified biophysical profile 
consisting of AFI and non-stress test, and adverse events), and neonatal observations (Apgar 
scores, growth parameters at birth and follow-up, gross development, and adverse events).  
 
Follow-up 
Women were discharged 6 hours after the end of the infusion or at the discretion of the 
investigator. Hospital records were reviewed to determine gestational age at birth; Apgar 
scores; and weight, length, and head circumference at birth. Infants were assessed 
approximately 1 month after birth. Neonatal adverse events were determined from either 
neonatal records or maternal reporting. 
 
Statistical Analyses  
The planned Bayesian statistical analysis declared statistical significance if the 95% credible 
interval (corresponding to the confidence interval) excluded 0 (for a difference) or 1 (for 
relative risk [RR]). Partially informative priors (probability distribution according to 
available data) from the dose-ranging study were used in the analyses of proportions of 
women achieving uterine quiescence and days to delivery. This was analogous to including 
data from a certain number of women from the prior study, as well as observed data from the 
present study, according to standard application of Bayes’ theorem [14]. A non-informative 
prior (analogous to analysis of the observed data from the study) was used for the analysis of 
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the proportion of preterm births and a sensitivity analysis (i.e. to evaluate the influence of the 
partially informative priors) for the endpoints of uterine quiescence and days to delivery. The 
planned sample size (n = 64) provided at least 86% power to detect a 40% absolute 
difference, or RR of 2.6, in the proportion of women achieving uterine quiescence.    
The safety and analysis populations were defined as all women who received at least one 
dose of study drug. For the primary endpoint of uterine quiescence, women who stopped the 
study drug within 6 hours of time zero were recorded as non-responders. For analyses of days 
to delivery and proportion of preterm births, actual birth data were used.    
Uterine quiescence response rates for each treatment group and the relative risks (defined as 
the ratio of retosiban to placebo response rates) along with 95% credible intervals were 
estimated by using a Bayesian formulation of Fisher’s exact test. The proportion of women 
delivering preterm was similarly analysed. The mean difference in days to delivery between 
treatment groups, along with the 95% credible interval, was estimated from a Bayesian 
formulation of an analysis of covariance model with gestational age at entry fit as a 
continuous covariate. No other hypothesis tests were performed, according to the protocol. 
All statistical analyses were performed with SAS/IML
®
 (SAS Software, Cary, NC, USA) or 
the R open-source software environment for statistical computing.  
Details of ethics approval: Written informed consent was obtained from all women. The 
study was conducted in compliance with Good Clinical Practice and the Declaration of 
Helsinki (2008) and was approved by the following institutional review boards: CPP Ile-de-
France XI, Saint-Germain-en-Laye 78105, France, ref. 174142/063858; St. Joseph’s 
Hospital and Medical Center Institutional Review Board for Human Research, Phoenix, AZ 
85013, USA , ref. 105422/034702; Sandhills Multi-Institutional Review Board, Pinehurst, 
NC 28374, USA, ref. 135920/048485; University of Tennessee Graduate School of 
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Medicine Institutional Review Board, Knoxville TN 37920, USA, ref. 129343/045389; Asan 
Medical Center IRB, Seoul 138-736, Korea, ref. 170633/061966; Singhealth Office of 
Research169611, Singapore, ref. 136524/048769; Western Institutional Review Board, 
Olympia, WA 98502, USA, ref. 184592/069282; TMC Institutional Review, Tucson, AZ 
85712, USA, ref. 166865/061308; Comite de Etica en Investigacion del Hospital 
Universitario Clinica San Rafael, Bogota/Cundinamarca, Colombia, ref. 205896/078327; 
Ethics Committee for Multicenter Trials, Sofia 1504, Bulgaria, ref. 171264/061999; 
Severance Hospital IRB, Seodaemun-gu, Seoul 120-752, Korea, ref. 170632/062795; 
Comite Etico de Investigacion Clinica, Hospital Universitario Vall d'Hebron 08035, 
Barcelona, Spain, ref. 171272/062160; CPP Ile-de-France XI, Saint-Germain-en-Laye 
78105, France, ref 174154/063864; Forsyth Medical Center Institutional Review Board, 
Winston-Salem, NC 27103, USA, ref. 037174/048486; Comite de Etica Medica en 
Investigacion, Bogota, Colombia, ref. 205915/078324; ArrowHead Regional Medical Center 
IRB, Colton, CA 92324, USA, ref. 120625/040718; Ethics Committee for Multicenter 
Trials, Sofia 1303, Bulgaria, ref. 171265/062002; University of Texas Medical Branch IRB, 
Galveston, TX 77555, USA, ref. 126172/034700.  
 
RESULTS 
Seventeen centres enrolled, randomised, and treated 64 women (Figure 1). One additional 
subject was randomised but not dosed because of labour progression; her data are not 
included in this report. Six women did not complete the retosiban infusion due to lack of 
response (n = 2) or a decision on the part of the subject or investigator (n = 4). The principal 
reasons for discontinuation of the infusion in the placebo group (n = 12) were lack of 
response (n = 7), adverse event (n = 3), or subject or investigator decision (n = 2). 
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Demographic and baseline characteristics of women participating in the study are 
summarised in Table 1. The groups were well matched. Patients were primarily white 
women in their mid-to-late twenties, and ranging in age from 18 to 41 years. There was a 
slight imbalance in randomisation, with fewer retosiban patients  (9/30 vs. 15/34) randomised 
to the earlier gestational age group, although the increased rate of discontinuation of drug in 
the placebo group resulted in a similar number of patients completing the infusion  in each 
study arm (22 and 20 for retosiban and placebo, respectively). A protocol amendment was 
introduced after the first 12 women were enrolled for stratification by gestational age to 
ensure future balanced randomisation. Although there is an imbalance of the number of 
women in the early gestational age group across treatments, analyses indicated that the effect 
of retosiban versus placebo was similar across gestational ages. 
 
Pharmacodynamic and Efficacy Outcomes 
 
Uterine Contractions 
Uterine quiescence was achieved in 62% of women who received retosiban compared with 
41% who received placebo. The RR was 1.53 (95% CrI: 0.98, 2.48; NS). The mean baseline 
contraction rates were 12.5 and 12.9/hour in the retosiban and placebo groups, respectively. 
The rates at hour 6 were 3.7 and 5.3, respectively (Figure 2). 
 
Intravenous infusion rates were increased in 37% (11/30) and 62% (21/34) of women 
assigned to retosiban and placebo, respectively. Ten women received rescue tocolysis: three 
(10%) in the retosiban group and seven (21%) in the placebo group. Rescue tocolytics 
included magnesium sulphate (n = 6), nifedipine (n = 3), fenoterol (n = 2), ritodrine (n = 1), 
atosiban (n = 1), and salbutamol (n = 1).  
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Time to Delivery and Preterm Births 
The time to delivery was longer in women treated with retosiban compared with placebo 
(mean difference 8.2 days [95% CrI: 2.7, 13.74]; median time to delivery: 34.5 and 25 days, 
respectively). There were no deliveries within 7 days in the retosiban group, but six births 
(17.6%) in the placebo group. The time to delivery at each gestational age for women who 
received retosiban or placebo is shown in Figure 3. 
 
The proportion of preterm births in the retosiban and placebo groups was 18.7% (95% CrI: 
7.4%, 33.7%) and 47.2% (95% CrI: 31.4%, 63.4%), respectively. The RR of preterm birth in 
women treated with retosiban was 0.38 (95% CrI: 0.15, 0.81). 
 
Statistical Inference 
Partially informative priors from the dose-ranging study (data from 14 subjects treated with 
retosiban IV and 5 treated with placebo IV) were included in the evaluation of uterine 
quiescence and time to delivery. The analyses were repeated using non-informative priors, 
which indicated that the use of these partially informative priors from the dose-ranging study 
had no impact on the statistical inferences, although there were minor changes to the point 
estimates and 95% CrI, as shown in Table 2. 
Safety 
Maternal Assessments 
Results from maternal ECGs, vital signs, and clinical laboratory assessments were 
comparable for both groups. There were no significant changes in maternal blood pressure 
with treatment; mean systolic and diastolic blood pressures following infusion of retosiban or 
placebo (0–48 hours) are shown in Figure 4. Maternal adverse events and serious adverse 
events were generally similar across treatment groups. There were 14/30 (47%) adverse 
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events and 2/30 (7%) serious adverse events reported in the retosiban group, compared with 
17/34 (50%) and 2/34 (6%) in the placebo group. Adverse events are displayed in Table 3 
and a summary of serious adverse events is shown in Table 4. There was one report of 
postpartum haemorrhage that occurred more than 30 days after the completion of retosiban. 
The event was considered not related to treatment. 
 
Fetal Assessments 
There were no significant changes in the modified biophysical profile and values were similar 
across all treatment groups. Fetal heart rate parameters were not significantly different in 
women treated with retosiban or placebo. In one woman in the placebo group, there was a 
fetal heart rate deceleration that resolved spontaneously. Mean fetal and maternal heart rates 
following maternal administration of retosiban or placebo (0–48 hours) are shown in Figure 
5. 
 
Neonatal Assessments 
Apgar scores and growth parameters were consistent with those expected for the estimated 
gestational age at birth and were similar across groups. Neonatal endpoints and gross 
developmental follow-up at approximately 1 month are summarised in Table 5A, B.  
Adverse events were reported in 4/30 (13%) and 7/34 (21%) of retosiban- and placebo-
exposed neonates, respectively. Adverse events in newborns are summarised in Table 6. Two 
of 30 (7%) neonates whose mothers received retosiban had a serious adverse event reported 
compared with 3/34 (9%) of placebo-exposed neonates (Table 7). Neonatal adverse events 
and serious adverse events were generally associated with preterm birth complications or had 
confounding risk factors.  
  
This article is protected by copyright. All rights reserved. 
DISCUSSION 
The results of this study demonstrate that short-term treatment with retosiban significantly 
prolongs pregnancy and reduces the incidence of preterm birth. Few, if any, placebo-
controlled studies have demonstrated an effect of this magnitude [7, 15, 16]. This is 
encouraging, as data on the efficacy of current tocolytics are contradictory and adverse 
effects have been reported in mothers or offspring [17]. To date, no tocolytic has been 
demonstrated effectively to delay delivery and improve outcome, although some agents, such 
as the beta-sympathomimetics, have been demonstrated to delay delivery [18]. This 
represents a dilemma, since it is known that babies born at later gestational ages have lower 
morbidity and mortality, yet delaying delivery has not been shown to improve outcome [9]. 
There are many possible explanations, such as methodological issues in the clinical trials or 
failure to use the time to perform procedures that improve outcome. More worrying is the 
possibility that administration of a tocolytic could theoretically maintain the fetus in an 
adverse intrauterine environment. In light of this, it is important that patients are carefully 
selected for tocolysis, with exclusion of those having aetiological factors, such as abruption 
or intrauterine infection, which could adversely influence the outcome. The results of this 
study demonstrate a significant prolongation in time to delivery in women administered 
retosiban for the treatment of preterm labour and form the basis for phase 3 trials that will 
determine whether the prolongation of the pregnancy is associated with improved outcomes 
in the offspring.  
 
Additional studies are in progress to further elucidate the mechanisms of retosiban action on 
the myometrium and other tissues, such as the amnion. Interestingly, in the present study 
there was a marked increase in the duration of pregnancy following a single, time-limited 
infusion. This observation raises questions about the pathophysiology of preterm labour, and 
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suggests that in this patient population the initiating stimulus may be discrete, self-limited, 
and non-recurrent. 
 
The retosiban infusion was well tolerated, and there was no indication of a safety issue for 
mother, fetus, or newborn. A theoretical safety concern with retosiban is an increased risk of 
postpartum haemorrhage if delivery occurs within a few hours of infusion. A case of 
postpartum haemorrhage occurred more than 30 days after retosiban and was not considered 
related to treatment. Because of the mechanism of action of retosiban and the role of oxytocin 
in promoting haemostasis after delivery, it will be important to monitor similar events in 
subsequent trials. 
 
Treatment discontinuations and dose escalations provide evidence that the initial retosiban 
dosing regimen, consisting of a 6-mg loading dose and 6-mg/hour infusion, is the lowest 
effective dose. More women discontinued study drug in the placebo group than in the 
retosiban group. In addition, more women taking placebo had their infusion rates increased 
compared with women taking retosiban (65% vs. 37%). As almost 40% of women on 
retosiban required a dose increase, it is unlikely that a dose lower than 6 mg/hour would 
provide adequate effect. Taken together, the data from this study support the initial 6-
mg/hour infusion rate as the lowest effective dose for the majority of women, while 
recognising that a considerable number of women may require higher doses to attain a 
satisfactory response. 
 
Strengths and Limitations 
The strength of this study is that it provides evidence for the efficacy, safety, and tolerability 
of a specific oxytocin receptor antagonist for the treatment of spontaneous preterm labour, 
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and thus represents a proof-of-concept study in this population. It is perhaps surprising that 
the effects on time to delivery, preterm birth, and use of rescue tocolysis were so marked, 
given the heterogeneous population typical of such studies. The difference in the effect on 
uterine quiescence between active treatment and placebo groups was not statistically 
significant, although there was a markedly higher rate of quiescence in women who received 
retosiban (62% vs. 41%).  A potential limitation of this study is that it was not, nor was it 
intended to be, a definitive trial to demonstrate the effectiveness of retosiban in clinical 
practice. Nor was it designed to demonstrate improved neonatal morbidity and mortality; 
there was no long-term neonatal follow-up. The inclusion criteria, similar to many prior trials 
investigating tocolytic agents, did not include fetal fibronectin or cervical ultrasound, which 
may be used in clinical practice. Furthermore, women at early gestational ages (<30 weeks) 
were not recruited.  
 
The advent of a therapeutic intervention that could significantly prolong pregnancy in 
patients with spontaneous preterm labour would be invaluable. While the mode of action of 
retosiban in preterm labour is not fully understood, this placebo-controlled study found that 
the short-term administration of retosiban halted preterm labour and prolonged pregnancy to 
a degree that could have a positive impact on perinatal outcomes. 
 
CONCLUSION  
In conclusion, this phase 2 study provides proof-of-concept evidence for the efficacy and 
safety of retosiban, a prerequisite for investment in phase 3 clinical trials. Whether the 
tocolytic effect of retosiban results in improved neonatal and infant outcomes following 
preterm labour at early and late gestational ages remains to be determined.   
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FIGURE LEGENDS 
 
Figure 1.  Disposition of women in proof-of-concept study (IP=investigational product). 
Figure 2.  Mean uterine contraction frequency.  
Figure 3. Scatter plot of days to delivery versus gestational age at randomisation. The solid 
line represents the time in days to achieve 37 weeks. Women falling below the solid line 
delivered before 37 weeks and those above the line delivered after 37 weeks. The dashed red 
and blue lines display the linear fit for time to delivery for the retosiban and placebo groups, 
respectively. The difference between the red and blue lines represents the difference between 
retosiban and placebo in mean days to delivery, which was consistent across gestational ages.  
Figure 4. Maternal blood pressure (mean and 95% CrI) following administration of retosiban 
or placebo (0‒ 48 hours). 
Figure 5. Maternal and fetal heart rate (mean and 95% CrI) following maternal treatment 
with retosiban or placebo (0‒ 48 hours).  
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Table 1.  Summary of subject demographic and baseline characteristics 
Treatment group
 
Retosiban Placebo 
Number treated 30 34 
Age in years, mean (range) 25.2  
(18-39)  
27.8  
(19-41)  
BMI, mean (SD) 25.8 (4.4) 26.9 (4.3) 
Race, n (%)   
African American 4 (13) 2 (6) 
American Indian or Alaskan Native 1 (3) 2 (6) 
Asian  2 (7) 6 (18) 
White – Arabic/North African  1 (3) 0 
White – White/Caucasian/European 22 (73) 24 (71) 
Ethnicity, n (%)   
Hispanic or Latino 10 (33) 12 (35) 
Non-Hispanic or Latino 20 (67) 22 (65) 
Gestational age, n (%)   
 30
6/7
-32
6/7 
9 (30) 15 (44) 
 33
0/7
-35
6/7 
21 (70) 19 (56) 
Cervical dilatation, median cm 2  2 
Contraction frequency, mean (SD) 12.5 (7.5) 12.9 (6.0) 
Prior tocolytic, n (%) 6 (20) 10 (29) 
BMI, body mass index; SD, standard deviation. 
  
This article is protected by copyright. All rights reserved. 
Table 2. Effect of partially informative versus non-informative prior 
Prior Relative risk of uterine 
quiescence 
Difference in time to 
delivery 
Partially informative prior using data from 
phase 2 dose-ranging study 
1.53 
(95% CrI: 0.98, 2.48) 
8.2 
(95% CrI: 2.7, 13.74) 
Non-informative prior (phase 2a proof of 
concept study only) 
1.54 
(95% CrI: 0.94, 2.63) 
7.3 
(95% CrI: 1.0, 13.5) 
CrI: credible interval.  
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Table 3. Maternal adverse events
a 
Adverse event Retosiban
 
n = 30  
n (%) 
Placebo 
n = 34  
n (%) 
Headache 4 (13) 1 (3) 
Dyspepsia  3 (10) 1 (3) 
Back pain  2 (7) 0 
Nausea 2 (7) 1 (3) 
Abdominal pain, upper 1 (3) 1 (3) 
Amniotic fluid, decreased 1 (3) 1 (3) 
Constipation  1 (3) 1 (3) 
Premature rupture of membranes  1 (3) 2 (6) 
Paraesthesia 0 2 (6) 
Polyhydramnios 0 2 (6) 
Postpartum depression  0 2 (6) 
a 
Listed are all adverse events, regardless of treatment group. Women with more than 
one occurrence of the same type of adverse event are listed only once. 
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Table 4. Maternal serious adverse events
a 
 
Treatment Adverse event Investigator 
assessment of 
drug 
relatedness 
Comments 
Retosiban  Postpartum 
haemorrhage  
No The event occurred >30 days post 
discontinuation of retosiban 
Retosiban
 
Musculoskeletal 
pain  
No The event was secondary to a motor 
vehicle accident and occurred >26 days 
post discontinuation of retosiban 
Placebo  Amniotic fluid 
volume decreased  
No AFI decreased to 5.8 cm two days after 
completion of placebo infusion. Event 
resolved as AFI subsequently increased 
to 6.6 cm and 7.1 cm 
Placebo
 
Hypertension No Elevated systolic and diastolic blood 
pressure at 3-week postpartum visit, 
approximately 5 weeks after completion 
of placebo infusion. Admitted to hospital 
and blood pressure normalised with 
antihypertensives 
a 
A serious adverse event is any untoward medical occurrence that results in death, is life- 
threatening, results in hospitalisation or prolongation of existing hospitalisation, results in 
disability/incapacity, is a congenital anomaly/birth defect, drug-induced liver injury, or any 
other event deemed medically important. 
AFI, amniotic fluid index. 
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Table 5A,B. Neonatal Outcomes 
A. Neonatal endpoints  
 Treatment Time point N n Mean (SD) 
Apgar Score at 
1minute 
 
Retosiban Birth 30 30 8.3 (0.88) 
PBO Birth 34 34 8.2 (0.77) 
     
Apgar Score at 5 
minutes 
  
  
Retosiban Birth 30 30 9 (0.53)  
 
PBO Birth 34 34 8.9 (0.34) 
          
  
Length (cm) 
  
  
  
  
  
Retosiban Birth 30 28 47.8 (2.78) 
PBO Birth 34 34 47.8 (3.39) 
          
  
Retosiban Follow-up 30 22 50.6 (2.89) 
PBO Follow-up 34 29 51.3 (3.3) 
          
  
Neonatal weight 
(g) 
  
  
  
  
Retosiban Birth 30 30 3099 (512.6) 
PBO Birth 34 34 2940 (585.0) 
          
  
Retosiban Follow-up 30 22 3427 (635.5) 
PBO Follow-up 34 30 3602 (659.5) 
     
Neonatal head 
circumference 
(cm) 
Retosiban Birth 30 27 33.3 (1.78) 
PBO Birth 34 34 33.1 (1.63) 
          
This article is protected by copyright. All rights reserved. 
  
  
  
  
  
Retosiban Follow-up 30 21 35.1 (1.75) 
PBO Follow-up 34 27 35.2 (1.77) 
          
  
Time to follow-
up (days) 
  
Retosiban Follow-up 30 22 18.4 (15.67) 
PBO Follow-up 34 31 25.1 (20.45) 
       B. Gross development reported at follow-up  
Gross 
development  
Treatment n Norm
al 
Abnor
mal 
Not reported 
Retosiban 30 22 0 8 
PBO 34 30 1 3 
 
  
This article is protected by copyright. All rights reserved. 
Table 6. Adverse events occurring in neonates
a 
Adverse event Retosiban 
n=30 (%) 
Placebo 
n=34 (%) 
Hypoglycaemia 2 (7) 1 (3) 
Hyperbilirubinaemia  1 (3) 5 (15) 
Jaundice 1 (3) 1 (3) 
Anaemia 0 2 (6) 
Hypercalcaemia 0 2 (6) 
Malnutrition
b
 0 2 (6) 
a 
Listed are all adverse events, regardless of treatment group. Neonates with more than 
one occurrence of the same type of adverse event are listed only once. 
b 
Medical Dictionary for Regulatory Activities (MedDRA) preferred term for event 
reported as nutrition imbalance (infant). 
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Table 7. Neonatal serious adverse events
a 
Serious adverse event Retosiban 
n = 30 (%)
 
(events occurred in  
two neonates) 
Placebo 
n = 34 (%)
 
(events occurred in 
three neonates) 
Hyperbilirubinaemia 1
b
 (3) 
 
2 
c,d 
(6%) 
Hypoglycaemia  1
e
 (3) 
 
0 
Jaundice 1
e
 (3) 
 
0 
Meconium in amniotic fluid  1
e
 (3) 
 
0 
Apnoea 0 1
d
 (3) 
 
Malnutrition
f
 0 2
c,d
 (6) 
 
Respiratory distress 0 1
d
 (3) 
 
Tachypnoea 0 1
g
 (3) 
 
a
 A serious adverse event is any untoward medical occurrence that results in death, is 
life- threatening, results in hospitalisation or prolongation of existing hospitalisation, 
results in disability/incapacity, is a congenital anomaly/birth defect, drug-induced 
liver injury, or any other event deemed medically important. 
b 
37-week infant. Investigator noted a maternal/fetal blood group incompatibility 
(mother A+; infant O+). 
c
 Delivered at 33 weeks’ gestation. 
d 
Delivered at 31 weeks’ gestation. 
e
 Infant born to a mother with gestational diabetes (risk of neonatal hypoglycaemia) 
following post-date induction (risk of meconium). Investigator attributed neonatal 
jaundice to maternal-fetal blood group incompatibility.  
f 
Medical Dictionary for Regulatory Activities (MedDRA) preferred term for event 
reported as nutrition imbalance (infant). 
g 
Delivered at 34
6/7
 weeks’ gestation. 
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